Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Next Science's share price is A$0.145.
Next Science's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.12. Hence, Next Science's PS Ratio for today is 1.23.
Good Sign:
Next Science Ltd stock PS Ratio (=0.01) is close to 10-year low of 0.01.
The historical rank and industry rank for Next Science's PS Ratio or its related term are showing as below:
ASX:NXS'
s PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 8.96 Max: 85
Current: 0.01
During the past 7 years, Next Science's highest PS Ratio was 85.00. The lowest was 0.01. And the median was 8.96.
ASX:NXS's PS Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.36
vs ASX:NXS: 0.01
Next Science Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Next Science was -12.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 37.30% per year.
During the past 7 years, Next Science's highest 3-Year average Revenue per Share Growth Rate was 74.10% per year. The lowest was 20.10% per year. And the median was 32.60% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Next Science PS Ratio Related Terms
Next Science PS Ratio Historical Data
* Premium members only.
The historical data trend for Next Science's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's PS Ratio distribution charts can be found below:
* The bar in red indicates where Next Science's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Next Science's PS Ratio for today is calculated as
Next Science's Share Price of today is A$0.145.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Next Science (ASX:NXS) has a PS Ratio of 1.23 as of Aug. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Next Science and its competitors. This is 86% below median its historical median of 8.96. Over the past decade, Next Science's PS Ratio has ranged from 0.01 to 85.00.
Is Next Science's PS Ratio too high?
Next Science's current PS Ratio of 1.23 is 86% below median its 10-year median of 8.96. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 85.00. The Drug Manufacturers industry median PS Ratio is 2.36. Next Science's value of 1.23 is 47.9% below this industry median. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's PS Ratio compare to GCAN and PTPI?
Next Science's PS Ratio of 1.23 can be compared against companies in the Drug Manufacturers industry. The industry median PS Ratio is 2.36. Next Science's value of 1.23 is 47.9% below this benchmark. Historically, Next Science's own PS Ratio has ranged from 0.01 to 85.00 over the past decade. While the company's 10-year median is 8.96 vs. the industry median of 2.36, Next Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.36, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Next Science's current PS Ratio of 1.23 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current PS Ratio is 1.23, which is 86% below median its own 10-year median of 8.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current PS Ratio of 1.23. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current PS Ratio is 1.23, which is 86% below median its 10-year median of 8.96 and 47.9% below the Drug Manufacturers industry median of 2.36. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Next Science (ASX:NXS), the current PS Ratio is 1.23 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Next Science (ASX:NXS) Overvalued in 2026?
Based on GuruFocus' analysis, Next Science stock appears to be undervalued.
The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.
Key valuation signals for ASX:NXS:
PS Ratio: 1.23 (86% below median its 10-year median of 8.96)
GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
Industry Position: 47.9% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score
Get the complete analysis for ASX:NXS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NXS has been successfully added to your 
